Devices/drugs to remain under DG Sanco in newly approved EU Commission
This article was originally published in Clinica
Oversight of medical device and drug policy in the EU is to remain with the European Commission’s health directorate (DG Sanco), and not with the industry directorate (DG ENTR). The news was announced just before the European Parliament today voted in favor of the new European Commission, which will be led by President Jean-Claude Juncker and officially begin work on 1 November. There were 423 votes for the new commission and its new college of commissioners, 209 votes against and 67 abstentions.
You may also be interested in...
Switzerland’s current economic and trading relationship with the UK is based on its MRA with the EU. So, where does this leave the two countries in trading with one another now each of their relationships with the EU are under threat?
With fewer than a hundred days left before the EU Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss in this week's podcast growing concerns by medtech industry members that they may not be ready in time to comply with the regulations and may inadvertently run afoul of them.
What will the fall-out of political tensions between the EU and Switzerland mean for notified bodies based in Switzerland, and for the future recognition of CE marks granted in one of the most important medtech markets in Europe?